Price Targets
PAYS
Analysts have updated their ratings and price targets for PaySign (NASDAQ:PAYS), showing a positive shift in sentiment with an average price target increase to $5.0 from $4.25. The company has shown strong financial performance, including a revenue growth rate of 28.93%, a net margin of 41.07%, and an ROE of 26.36%. These updates and financial metrics suggest a bullish outlook for PaySign.
Portfolio Pulse from
Benzinga Insights
April 30, 2024 | 6:01 pm
RPAY
Analysts have provided diverse opinions on Repay Holdings (NASDAQ:RPAY), with recent ratings ranging from bullish to indifferent. Over the past quarter, 6 analysts have updated their views, showing a shift towards a more positive outlook. The average 12-month price target for RPAY has been raised to $12.92, indicating a 12.35% increase from the previous target of $11.50. Key financial indicators reveal RPAY's strong net margin and positive revenue trend, despite its market capitalization and ROE being below industry benchmarks.
Portfolio Pulse from
Benzinga Insights
April 30, 2024 | 6:01 pm
NRGV
Analyst ratings for Energy Vault Holdings (NYSE:NRGV) show mixed sentiments, with recent adjustments indicating a bearish outlook. The average 12-month price target has been lowered to $3.06 from $4.90, reflecting a significant drop. Analysts from firms like Stifel, Chardan Capital, and Goldman Sachs have adjusted their ratings and price targets, responding to market dynamics and company performance. Energy Vault Holdings, a grid-scale energy storage company, has shown a revenue growth rate of 17.86% as of December 31, 2023, but faces challenges in market capitalization and growth compared to industry benchmarks.
Portfolio Pulse from
Benzinga Insights
April 30, 2024 | 6:00 pm
NEO
NeoGenomics (NASDAQ:NEO) has received mixed analyst ratings over the past three months, with a recent shift towards a more bullish outlook. The average 12-month price target for NEO has increased to $20.5, reflecting a 2.5% rise from the previous target of $20.00. Analysts from Needham, Piper Sandler, and Goldman Sachs have adjusted their price targets and ratings, indicating changing perspectives on the company's market performance and financial health. NeoGenomics operates in genetic testing for cancer and has shown a revenue growth rate of 12.15% as of December 31, 2023, but lags in net margin and ROA compared to industry averages.
Portfolio Pulse from
Benzinga Insights
April 30, 2024 | 6:00 pm
LLY
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Eli Lilly and Co (LLY) and increased the price target from $815 to $885.
Portfolio Pulse from
Benzinga Newsdesk
April 30, 2024 | 5:46 pm
Previous
Next